FAM184B Inhibitors
FAM184B inhibitors encompass a range of chemical compounds that impede the functional activity of FAM184B through their specific actions on cellular signaling pathways and cytoskeletal dynamics. Staurosporine, as a broad-spectrum kinase inhibitor, potentially undermines the phosphorylation-dependent regulation of FAM184B, while rapamycin, by curtailing mTOR signaling, could attenuate processes such as cytoskeletal reorganization where FAM184B may be engaged. In a similar vein, Y-27632 and LY 294002 target key components of the cytoskeletal network, namely ROCK and PI3K respectively, which may render FAM184B less active by stabilizing the cytoskeleton or interruptingcell signaling that FAM184B is involved in. Brefeldin A and Cyclosporin A further contribute to the diminished function of FAM184B by disrupting vesicle trafficking and inhibiting calcineurin, affecting the broader cellular environment in which FAM184B operates. Microtubule dynamics, which are crucial to cell structure and function, are influenced by Colchicine, Nocodazole, and Taxol; each of these compounds alters microtubule behavior in a way that could potentially reduce the activity of FAM184B associated with this component of the cytoskeleton. Mitomycin C might indirectly hamper FAM184B's function by inducing DNA damage and cellular stress, leading to a reduction in the cellular context for FAM184B activity.
The second set of FAM184B inhibitors includes Blebbistatin and Wiskostatin, which specifically target actin and myosin dynamics. Blebbistatin's inhibition of non-muscle myosin II could decrease FAM184B's role in cell motility and contractility, while Wiskostatin's suppression of N-WASP-mediated actin polymerization could negatively impact any association between FAM184B and actin cytoskeletal dynamics. Each inhibitor's mode of action, whether it be kinase inhibition, modulation of cytoskeletal elements, or interference with cellular trafficking, contributes to an overall reduction in FAM184B's involvement in key cellular processes. This suite of inhibitors acts through their direct biochemical effects on molecular pathways to indirectly suppress the functional activity of FAM184B, delineating a network of intracellular routes by which FAM184B's activity can be diminished.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent, non-selective inhibitor of protein kinases. By inhibiting various kinases that phosphorylate FAM184B, Staurosporine may indirectly lead to the reduced activation and stabilization of the FAM184B protein. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that can disrupt mTOR signaling pathways. Since mTOR can be involved in the regulation of cytoskeletal organization, where FAM184B might play a role, inhibition of mTOR signaling can lead to diminished function of FAM184B in these processes. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of ROCK kinases. As ROCK kinases can influence cytoskeletal dynamics and cell migration, where FAM184B may be involved, Y-27632 can indirectly decrease the functional activity of FAM184B by stabilizing the cytoskeleton. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a PI3K inhibitor. PI3K signaling is involved in numerous cellular processes including those related to the cytoskeleton. Therefore, inhibiting PI3K can indirectly diminish the role of FAM184B in cytoskeletal organization and related functions. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A is an inhibitor of ADP-ribosylation factor (ARF), which is involved in vesicle trafficking. By inhibiting ARF, Brefeldin A may disrupt processes where FAM184B is potentially involved, thus indirectly decreasing its functional activity. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Cyclosporin A is an immunosuppressant that inhibits calcineurin. As calcineurin can affect various cellular pathways, including those related to cytoskeletal dynamics where FAM184B is implicated, its inhibition could lead to decreased functional activity of FAM184B. | ||||||
Colchicine | 64-86-8 | sc-203005 sc-203005A sc-203005B sc-203005C sc-203005D sc-203005E | 1 g 5 g 50 g 100 g 500 g 1 kg | $100.00 $321.00 $2289.00 $4484.00 $18207.00 $34749.00 | 3 | |
Colchicine binds to tubulin, inhibiting microtubule polymerization. Given that FAM184B may associate with the cytoskeleton, colchicine can indirectly decrease the functional activity of FAM184B by disrupting microtubule dynamics. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Nocodazole is a microtubule-depolymerizing agent. By disrupting microtubule organization, nocodazole can indirectly affect the functional activity of FAM184B if it is associated with microtubule dynamics. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $41.00 $74.00 $221.00 $247.00 $738.00 $1220.00 | 39 | |
Taxol is a microtubule stabilizer. Although it primarily stabilizes microtubules, it can indirectly diminish the activity of FAM184B by altering normal microtubule dynamics and potentially impacting its function. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $66.00 $101.00 $143.00 | 85 | |
Mitomycin C is a DNA crosslinker used in chemotherapy. By causing DNA damage and influencing cell cycle arrest, it may indirectly reduce the functional activity of FAM184B by decreasing the cellular context in which it operates. | ||||||